Nipogalin (Cefuroxime Sodium)

Cefuroxime sodium works by binding to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final stages of peptidoglycan cross‑linking. This disruption weakens the cell wall, leading to osmotic lysis and death of susceptible Gram‑positive and Gram‑negative bacteria.

The dosage of Nipogalin is determined by the prescribing clinician based on the type and severity of infection, patient age, weight, and renal function. The prescriber will select an appropriate dose and schedule for intramuscular or intravenous administration.

Safety data for cefuroxime sodium in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss individual risk factors with the patient and consider alternative therapies when appropriate.

To order Nipogalin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Nipogalin (cefuroxime sodium) offers broader Gram‑negative coverage than first‑generation cephalosporins while retaining activity against many Gram‑positive organisms. Compared with third‑generation agents, it has a lower risk of inducing resistance but may be less potent against certain resistant strains. Choice of therapy depends on the infection profile and local antimicrobial susceptibility patterns.

Nipogalin should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration. Follow aseptic technique during preparation and administration.

Nipogalin is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration must be performed by qualified healthcare personnel using aseptic technique. The injection site, volume, and rate are determined by the prescriber based on the clinical indication and patient characteristics.

Serious risks include anaphylactic reactions, severe Clostridioides difficile‑associated colitis, Stevens‑Johnson syndrome, hemolytic anemia, and significant renal or hepatic impairment. Patients should be monitored for signs of hypersensitivity, persistent diarrhea, skin eruptions, or changes in laboratory parameters during therapy.

Nipogalin is contraindicated in individuals with a known hypersensitivity to cefuroxime, other cephalosporins, or any component of the formulation. Caution is advised for patients with a history of severe allergic reactions to β‑lactam antibiotics. It should also be avoided in patients with severe renal impairment unless dose adjustments are made.